痛风性肾病 中国就医指南

Gouty nephropathy is a chronic kidney disorder resulting from the long-term deposition of monosodium urate (MSU) crystals in renal parenchymal tissue and urinary tract structures, primarily due to persistent hyperuricemia. It represents a systemic manifestation of gout that extends beyond articular involvement to cause progressive tubulointerstitial inflammation, crystal-induced fibrosis, and eventual decline in glomerular filtration rate (GFR). Pathogenesis centers on sustained serum uric acid levels exceeding 6.8 mg/dL—the saturation threshold for MSU crystallization—leading to intratubular crystal formation, obstructive uropathy, and activation of the NLRP3 inflammasome pathway. This triggers IL-1β–mediated tubulointerstitial injury, oxidative stress, endothelial dysfunction, and upregulation of profibrotic cytokines such as TGF-β and CTGF. Unlike acute uric acid nephropathy (often seen in tumor lysis syndrome), gouty nephropathy evolves insidiously over years or decades, frequently coexisting with hypertension, metabolic syndrome, chronic kidney disease (CKD) stages 2–4, and cardiovascular comorbidities. Epidemiologically, it affects approximately 10–20% of patients with chronic tophaceous gout and accounts for ~1% of all cases of end-stage kidney disease (ESKD) in high-income countries; prevalence rises significantly in aging populations and regions with high purine intake and obesity rates. Key risk factors include male sex (especially post-menopausal women), genetic variants in SLC2A9 and ABCG2 transporters, chronic diuretic use (e.g., thiazides), chronic kidney impairment (reduced uric acid excretion), excessive alcohol consumption (particularly beer), high-fructose diets, obesity (adipose tissue promotes uric acid production), and uncontrolled hypertension. Importantly, gouty nephropathy is often underdiagnosed because early-stage disease is asymptomatic—patients may remain normotensive and retain normal GFR until significant interstitial scarring has occurred. As renal function declines, symptoms such as nocturia, fatigue, mild edema, and subtle reductions in urine concentrating ability may emerge; advanced disease manifests with proteinuria (typically subnephrotic), elevated serum creatinine, hypertension refractory to standard therapy, and increased cardiovascular mortality. Quality of life is substantially impaired—not only by recurrent gout flares and chronic joint pain but also by progressive renal dysfunction limiting physical activity, dietary freedom, medication options, and employment capacity. Patients face heightened psychological burden, including anxiety about dialysis dependence, financial strain from lifelong urate-lowering therapy (ULT), and social stigma associated with visible tophi and mobility limitations. Early detection via serum uric acid monitoring, urinalysis (for uric acid crystals), renal ultrasound (showing hyperechogenicity or reduced corticomedullary differentiation), and eGFR tracking is critical. Management hinges on rigorous, sustained uric acid control (<5 mg/dL for tophaceous disease), avoidance of nephrotoxic agents, blood pressure optimization (target <130/80 mmHg), and lifestyle modification—making multidisciplinary care involving nephrologists, rheumatologists, and dietitians essential.

# 痛风性肾病治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：eGFR ≥60 mL/min/1.73m²、无明显尿毒症症状、血尿酸持续＞480 μmol/L伴肾功能轻中度受损者。

• •药物治疗（3个月疗程）：

- 肾保护药（RAS抑制剂+SGLT2i）：600–2,400元/疗程

• •检验检查费：尿微量白蛋白/肌酐比、24h尿尿酸、肾脏超声、eGFR动态监测等：850–1,600元

二、介入/核心治疗方案

适用人群：eGFR 30–59 mL/min/1.73m²、顽固性高尿酸血症（＞540 μmol/L）、合并痛风石或肾内尿酸结晶沉积证据者。

• •尿酸酶静脉治疗（培格洛替酶）：需住院，每2周1次×6次，含输液监护、过敏预处理：36,000–52,000元/疗程
• •术前检查费（含心电图、凝血功能、HIV/乙肝/丙肝筛查、肾动脉CTA）：2,100–3,500元

三、晚期/并发症治疗方案

适用人群：eGFR＜30 mL/min/1.73m²、进展至CKD 4–5期、合并肾性贫血/代谢性酸中毒/高磷血症者。

• •血液透析联合降尿酸管理（每周3次×3个月）：48,000–72,000元（含透析费、促红素、磷结合剂、尿酸监测）
• •肾移植评估及围术期管理（含HLA配型、供体筛查）：120,000–180,000元（不含移植手术费）

四、方案快速选择指南

• •预算有限/早期患者：首选保守治疗（≤3,000元/季度）
• •中重度肾损/反复发作：推荐尿酸酶介入治疗（≈4.5万元）
• •终末期合并多系统损害：启动透析+多学科协同管理（年均支出≥15万元）